Physician profile
Gregory Skuta
NPI 1437128865
$871.94
in general payments reported to CMS, 2019-2025
11 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $10.51 · 2021: $59.26 · 2022: $183 · 2023: $106 · 2024: $49.05 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $247.57 | 2019-2025 | Unity, Centurion, Simbrinza |
| Allergan, INC. | $182.02 | 2019-2022 | |
| Sight Sciences, INC. | $141.52 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Merz Pharmaceuticals, LLC | $80.98 | 2023 | Xeomin |
| Abbvie INC. | $74.38 | 2022-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $52.50 | 2019 | |
| Bausch & Lomb Americas INC. | $33.12 | 2022-2025 | Vyzulta, Miebo |
| Aerie Pharmaceuticals, INC. | $18.48 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.38 | 2019 | |
| Abb Con-Cise Optical Group LLC | $10.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Skuta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.